4.6 Letter

Corticosteroids and infliximab impair the performance of interferon-γ release assays used for diagnosis of latent tuberculosis

Journal

THORAX
Volume 72, Issue 10, Pages 946-949

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2016-209397

Keywords

-

Funding

  1. Southampton NIHR Wellcome Trust Clinical Research Facility
  2. UK National Institute for Health Research
  3. Cancer Research UK [23562] Funding Source: researchfish
  4. National Institute for Health Research [CL-2011-26-004] Funding Source: researchfish

Ask authors/readers for more resources

The impact of immunosuppression on interferon-gamma release assays and novel cytokine biomarkers of TB infection, mycobacteria-specific IL-2, IP-10 and TNF-alpha responses was investigated in an ex vivo model. Cytokine responses in standard QuantiFERON-TB Gold in-Tube (QFT-GIT) assays were compared with duplicate assays containing dexamethasone or infliximab. Dexamethasone converted QFT-GIT results from positive to negative in 30% of participants. Antigen-stimulated interferon-gamma, IL-2 and TNF-alpha responses were markedly reduced, but IP-10 responses were preserved. Infliximab caused QFT-GIT result conversion in up to 30% of participants and substantial reductions in all cytokine responses. Therefore, corticosteroids and anti-TNF-alpha agents significantly impair interferon-gamma release assay performance. IP-10 may be a more robust TB biomarker than interferon-gamma in patients receiving corticosteroids.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available